Document is current

Article History

Received: 13 October 2019

Revised: 4 February 2020

Accepted: 17 February 2020

First Online: 6 March 2020

Conflict of interest

: A.J.M.: Consultancy from ADC Therapeutics, Erytech Pharma, Bristol-Myers Squibb, Cell Medica, Takeda Pharmaceuticals, Kyowa Hakko Kirin Pharma, miRagen Therapeutics Inc, Seattle Genetics. Research Funding from Bristol-Myers Squibb, Incyte, Kyowa Hakko Kirin Pharma, miRagen Therapeutics Inc, Seattle Genetics and Merck. Honoraria from Seattle Genetics. S.M.H.: Clinical research support/ Data safety monitoring board from ADC Therapeutics, AILERON, BeiGene, Celgene Corporation, Daiichi- Sankyo Co., Forty Seven, Inc., GlaxoSmithKline, Merck & Co., Inc., Miragen, Portola Pharmaceuticals, Inc., Seattle Genetics, Inc., Takeda/ Millennium, Trillium and Verastem. Scientific advisory boards, consultant or expert witness from Astex Pharmaceuticals, Celgene Corporation, Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., Portola Pharmaceuticals, Inc., Seattle Genetics, Inc., Takeda Pharmaceuticals North America, Inc. and Verastem. A.D.: Personal fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda, EUSA Pharma and research grants from National Cancer Institute and Roche. M.R.: Physicians’ Education Resource: Other: Provision of services; Celgene: Other: Provision of Services; Auron Therapeutics: Equity Ownership, Other: Provision of services. Other authors declare no relevant financial interests.